Cathy Kelly on Muck Rack

Cathy Kelly

Verified
Bethesda
As seen in: Informa, The Pink Sheet, MDedge |Psychiatry, Citeline, Generics Bulletin, HBW Insight, In Vivo, Medtech Insight, Scrip, MMIT (Managed Markets Insight & Technology), Friends of Cancer Research, Lookout Santa Cruz and
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Cathy

Contact Cathy, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

‘Significant Number of Applications’ For GENEROUS MFN Model Arrive Despite Questions

|
By Maaisha Osman , Cathy Kelly 
| The Pink Sheet
CMS dangled the possibility that GENEROUS participants could be exempt from a mandatory Most Favored Nation pricing model in Medicare Part D known as GUARD, but questions had arisen about whether any companies beyond those with MFN agreements would participate. Drug manufacturers outside the initial 17 MFN dealmakers are in talks with states to join the GENEROUS model.
Open in Who Shared Issue with article?

MFN Deals Post-Trump: Launch Price Parity Would Be Hardest To Undo

|
By Cathy Kelly 
| The Pink Sheet
Unwinding Most Favored Nation pricing deals after the Trump Administration ends may be difficult, CMS Administrator Mehmet Oz said, and may not entirely be in manufacturers' control. If Congress does not codify MFN deals, what will happens when Trump leaves office? (Shutterstock) Key Takeaways If manufacturers try to opt out of some provisions in their Most Favored Nation deals after President Trump leaves office, the launch pricing commitment could be the hardest to undo.
Open in Who Shared Issue with article?

Lilly Threatens To Cut Off 340B Providers Balking At Providing In-House Pharmacy Claims

|
By Cathy Kelly 
| The Pink Sheet
The initiative is part of an industry full-court press to promote 340B program transparency as HRSA restarts its rulemaking on a 340B rebate model. Hospitals and Lilly are waging dueling campaigns on access to 340B pharmacy claims. (Shutterstock) Key Takeaways Lilly is threatening to cut off 340B discounts to providers that do not comply with its request to submit 340B claims for drugs dispensed through in-house pharmacies.
Open in Who Shared Issue with article?
See all 1,522 articles

Actions

Share this page

Get in touch with Cathy

Contact Cathy, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified